Experimental study on the treatment of gastric cancer by TK gene combined with mIL-2 gene

World Chinese Journal of Digestology

Volumn 8, Issue 9, 2000, Pages 974-978

  Shan Yu Guo, ^a   Qin Long Gu, ^a   Bing Ya Liu, ^a   Zheng Gang Zhu, ^a   Hao Ran Yin, ^a   Yan Zhen Lin, ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; MIL 2 gene; Stomach neoplasm therapy; TK gene

Indexed keywords

LIPOSOME;

ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; RETROVIRUS; STOMACH CANCER; SUICIDE GENE; TRANSGENE;

EID: 0033795997     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Gene therapy for cancer
2. Tumor chemosensitivity conferred by inserted herpes thymidine Kinase genes; paradigm for a prospective cancer control strategy
3. Gene therapy for cancer: What have we done and where are we going?
4. Gene therapy and liver diseases
5. Antisense telomerase RNA induced human gastric cancer cell apoptosis
6. The basic science of gene therapy
7. Suicide gene therapy of tumors in digestive system
8. Current status of gene therapy in gastroenterology
9. Progress in studies on gene therapy for gastric cancer
10. Targeting chemo-therapy: A new focus in gene therapy vesearch
11. The TMC worldwide gene therapy enrollment report, end 1996
12. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
13. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma
14. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
15. Retroviral mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
16. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with Hsvtk retroviral gene therapy
17. Construction of retroviral vector carrying HSV-tk gene under control of human AFP enhancer corn sequence and human pgk promotor
18. Construction of retroviral vectors to induce a strong expression of human class I interferon gene in human hepatocellular carcinoma cells in vitro
19. Gene therapy for human colorectal carcinoma using human CEA promoter controled bacterial ADP-ribosylating toxin genes human CEA: PEA and DTA gene transfer
20. Suicide gene therapy of chemically induced mammary tumor in rat: Efficacy and distant bystander effect
21. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase
22. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells
23. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice
24. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: Implications for gene therapy
25. Effect of Herpes Simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'
26. Construction of human colorectal carcinoma-specific retroviral vector containing cytosine deaminase gene
27. Construction of retroviral vector containing HSV-tk gene for colorectal carcinoma tissue-specific gene therapy
28. Killing effect of 5-FC/ CD system on nude mice bearing human colorectal carcinoma
29. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation
30. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions
31. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions
32. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
33. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
34. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro
35. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
36. Enzyme/ prodrug gene therapy: Comparison of Cytosine Deaminase/ 5-Fluorocytosine Versus Thymidine Kinase/ Ganciclovir enzyme/ prodrug systems in a human colorectal carcinoma cell line
37. Glioma cells transduced with an Escherichia coli CD/Hsv-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
38. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes
39. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells
40. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
41. Immune system in suicide gene therapy
42. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-Fluorocytosine and induce protective immunity to wild type tumor
43. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
44. Cellular and tumoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
45. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
46. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
47. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
48. Immunotherapy of malignancy by in vivo gene transfer into tumors
49. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
50. A cyclic guanosine analogs inhibit DNA polymarases α, δ and ε with very different potencies and have unique mechanisms of action
51. In vivo analysis of the 'bystander effect': A cytokine cascade
52. A 'distant' bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor
53. Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation
54. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model
55. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival
56. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study
57. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
58. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
59. + T-cell immunity